Information Provided By: 
Fly News Breaks for January 6, 2016
CMRX
Jan 6, 2016 | 06:43 EDT
Piper Jaffray analyst Joshua Schimmer says he's "not throwing in the towel" on Chimerix and upped his price target for the shares to $11 from $10. With a cash position of $380M, the stock has "strong downside support" as the company assesses its next steps, Schimmer tells investors in a research note. The analyst is "increasingly optimistic" that the negative SUPPRESS results will not preclude registration and approval for treatment of active infections in immunocompromised patients. He reiterates an Overweight rating on the stock.
News For CMRX From the Last 2 Days
There are no results for your query CMRX
